|
Hutchmed China Ltd on Wednesday said it had launched a Phase I/IIa clinical trial of its cancer treatment HMPL-A580. Shares in the Hong Kong-based pharmaceutical firm rose 0.6% to 204.41 pence each around midday on Wednesday in London. HMPL-A580 is Hutchmed’s second novel antibody-targeted therapy conjugate. It is under investigation for patients with unresectable, advanced or metastatic solid tumours in China and the US, with the first study participant dosed on Wednesday. The drug company sees HMPL-A580 as a ‘first-in-class’ therapy. During phase I of the trial, ‘patients will receive HMPL-A580 intravenously at predefined dose levels to determine the maximum tolerated dose and recommended dose for expansion,’ Hutchmed explained. Phase IIa will focus on dose expansion and optimisation, providing further information on the drug’s safety and efficacy in treating selected solid tumors, ‘and to determine the recommended dose for the next phase,’ Hutchmed added. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
